Table 1.
Characteristics of participating antiretroviral therapy (ART) programmes.
| Sites | No. of patients | Female (%) | Median age in years (IQR) | No. on second-line ART with TDF (%) | Viral load monitoring | Follow-up time on second-line ART (py) | Mortality (95% CI) (per 1,000 py) | LTFU (95% CI) (per 1,000 py) |
|---|---|---|---|---|---|---|---|---|
| South Africa | ||||||||
| Aurum-C | 323 | 209 (65) | 38 (32–44) | 80 (25) | Yes | 309 | 6.5 (1.6–25.9) | 145.7 (108.8–195.1) |
| Aurum-W | 262 | 15 (6) | 45 (38–51) | 10 (4) | Yes | 331 | 45.2 (27.3–75.0) | 165.8 (127.3–216.0) |
| Khayelitsha | 197 | 144 (73) | 32 (28–40) | 13 (7) | Yes | 227 | 30.8 (14.7–64.7) | 61.7 (36.5–104.1) |
| Themba Lethu | 562 | 341 (61) | 36 (32–43) | 81 (14) | Yes | 766 | 35.3 (24.2–51.4) | 105.8 (85.1–131.5) |
| Tygerberg | 212 | 139 (66) | 35 (31–42) | 22 (10) | Yes | 329 | 39.5 (22.9–68.0) | 54.6 (34.4–86.7) |
| Zambia | ||||||||
| CIDRZ | 1,687 | 954 (57) | 38 (33–45) | 1,350 (80) | No | 2,508 | 25.1 (19.6–32.2) | 127.2 (114.0–141.9) |
| Total | 3,243 | 1,802 (55.6) | 38 (32–45) | 1,556 (48.0) | 4,471 | 28.4 (23.9–33.8) | 119.0 (109.3–129.5) | |
Py, person-years; LTFU, loss to follow-up; Aurum-C, Aurum Community cohort; Aurum-W, Aurum workplace cohort.